Behind the Consultant Curtain: What Kind of Oncology Company Are You?

Posted by Malik Kaman on Dec 12, 2017 2:21:03 PM

Maria Whitman and Sankalp Sethi co-wrote this blog post with Malik Kaman. This blog post is part one in a two-part series.

At ZS, we’ve advised companies on more than 90% of the launches in oncology over the past five years, so manufacturers frequently ask us how they compare to others in terms of their people, their processes and their capabilities. This is a great question. With the pace of oncology investment worldwide—oncology is expected to be 21.25% of total pharma sales in 2020 globally, according to a Quintiles analysis—the level of competition in this space has risen to a whole new level. As we think about what it will take to compete and win in the new reality, it’s important to consider the commercial advantages and disadvantages of who you are as a company—your people, processes and capabilities—not just what scientific innovations you can bring.


>
Read More

MACRA: A Stepping-Stone for Broader Changes

Posted by Christina Corridon on Dec 11, 2017 12:00:00 PM

Howard Deutsch co-wrote this blog post with Christina Corridon.

In its current form, the Medicare Access and CHIP (Children’s Health Insurance Program) Reauthorization Act (MACRA) of 2015 directly impacts the reimbursement rates and methodology of the physician fee schedule under Medicare Part B. However, MACRA is unlikely to have a significant impact on physician behavior or drug choice. Nonetheless, MACRA is part of a larger transition of payment based on volume to payment based on value (quality and cost reduction). Physicians will be penalized for continuing with “business as usual,” and newfound attention to tracking and reporting outcomes will be rewarded.


>
Read More

Improving Drug Development: A Call to Action

Posted by Malik Kaman on Nov 9, 2017 9:39:46 AM

Joe Keller, Chris Crabtree and Sarah Jegasothy co-wrote this article with Malik Kaman. 

If you’ve missed the transformation of the oncology therapeutic landscape over the past five years, you’ve had your head in the sand. While many recent advancements are hugely beneficial, one result of this tidal wave of investment is that some new drugs offer only marginal improvements yet command outrageous price tags. This is a controversial issue and should give everyone in oncology pause. 


>
Read More

Is it Time to Rethink PFS?

Posted by Pranav Srivastava on Oct 30, 2017 10:59:18 AM

Vinod Nair co-wrote this blog post with Pranav Srivastava.

Since the first guidelines on surrogate endpoints came out in 2003—codifying the idea that endpoints like progression-free survival (PFS), time-to-progression (TTP) and objective response rate (ORR) could be used to gain special approval—they’ve become a mainstay in oncology trial designs, with a significant increase in the number of abstracts reporting PFS as an endpoint.


>
Read More

Oncology Leads the Way for Field Medical

Posted by Jon Gonzales on Oct 23, 2017 8:00:00 AM

Sarah Jarvis and Sunil John co-wrote this blog post with Jon Gonzales. 

The medical affairs organization has seen a rapid increase in both growth and prominence in recent years, evolving from a minor support function to an integral strategic partner. Today’s complex healthcare ecosystem, along with a decline in physician access, means that pharmaceutical companies have become increasingly reliant on field medical teams to deliver scientific information to a growing base of stakeholders. Yet despite this increase in importance, only 23% of companies believe that they have a “very well defined” strategic plan when it comes to the organizational and business aspects of their medical affairs organizations, according to new ZS research.  


>
Read More